Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP
3',5'-cAMP + diphosphate
-
-
-
?
ATP
3',5'-cAMP + diphosphate
ATP
3',5'-cyclic AMP + diphosphate
ATP
3',5'-cyclic-AMP + diphosphate
additional information
?
-
ATP
3',5'-cAMP + diphosphate
-
-
-
-
?
ATP
3',5'-cAMP + diphosphate
-
-
-
?
ATP
3',5'-cAMP + diphosphate
-
cAMP synthesis by the AC6 isoform is not tightly coupled to cAMP hydrolysis, whereas for the other AC isoforms cAMP synthesis and hydrolysis are much more tightly linked
-
-
?
ATP
3',5'-cAMP + diphosphate
-
catalytic heterodimer VC1-IIC2
-
-
?
ATP
3',5'-cAMP + diphosphate
-
stable co-expression of AC2 with h5-HT6 receptor in CHODUKX cell line displays dose-dependent cAMP accumulation following agonist treatment
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
-
690360, 690680, 691561, 691562, 692562, 693180, 693436, 693560, 693763, 693803, 693830, 693847, 694363, 694374, 694823, 707801, 707947, 710009, 716279 -
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
adenylate cyclase-activating polypeptide type 1 receptor, PAC1-R, is involved in cAMP signalling in the pituitary gland
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
Ca2+-dependent adenylyl cyclases play a specific role in recovery from adaptive presynaptic silencing, involvement of the cAMP pathway in the basal balance between silenced and active synapses, as well as the recovery of baseline function after depolarization-induced presynaptic silencing, e.g. by glutamate, although isozymes AC1 and AC8 are not crucial for the baseline balance between silent and active synapses, overview. But AC8 plays a particularly important role in rapidly resetting the balance of active to silent synapses after adaptation to strong activity
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
capacitative Ca2+ entry via plasma membrane pore-forming component Orai1, i.e. Ca2+ release-activated Ca2+ modulator 1 or CRACM1, and stromal interacting molecule 1, STIM1, regulates adenylyl cyclase type 8, other modes of Ca2+ entry, including those activated by arachidonate and the ionophore ionomycin, are ineffective, detailed overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
interaction of mu-opioid receptors with G proteins and adenylyl cyclase in lumbar segments of the spinal cord, regulation, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
regulation of epithelial Na+ transport by soluble adenylyl cyclase in kidney collecting duct cells, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
soluble isozymes sAC play a unique function in male germ cells, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the adenylyl cyclase signaling cascade is involved in nicotine dependence and withdrawal, but also mediates numerous other neurotransmitter responses, effects of nicotine on adenylate cyclase enzyme activity: adolescent nicotine exposure elicits persistent suppression of basal adenylate cyclase activity and eventual compromise of responses to beta-adrenergic receptor stimulation, with effects emerging in late adulthood, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme is involved in beta1-AR signaling system that modulates intracellular Ca2+ in the heart. The enzyme is involved in mediation of the antiarrhymthmic effect of electro-acupuncture in the heart, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme is one of the signal transducing systems implicated in the regulation of the cardiovascular system and plays a role in signaling in vascular smooth muscle cells, which is decreased by oxidative stress, induced by high glucose, along with the expression of Gialpha proteins, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme modulates the cardiovascular response of posterior hypothalamic adenosine A2A receptor stimulation, adenylate cyclase, but not guanylate cyclase, mediates the depressor and bradycardiac actions of adenosine A2A receptors, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the soluble adenylyl cyclase is the main producer of glucose-induced cAMP in INS-1E insulinoma cells, while the transmembrane adenylyl cyclase does not play a role, overview
-
-
?
additional information
?
-
netrin-1 does not alter cAMP levels in axons attracted by this cue, and soluble adenylyl cyclase is not required for axon guidance to netrin-1
-
-
?
additional information
?
-
-
reduction of adenylyl cyclase activity induced by NaF and the increase in the Gi/Gs ratio can explain the changes in neurotransmission in olfactory bulbectomy rats, overview. Two weeks after surgery and compared to sham controls, olfactory bulbectomy rats display reduced NaF-stimulated adenylyl cyclase activity and increased Gi/Gs ratios in the hypothalamus, pre-frontal and cingulate cortices but not in the amygdala, hippocampus and caudate nucleus. No differences are found in basal or forskolin-stimulated conditions
-
-
?
additional information
?
-
soluble adenylyl cyclase inhibition blocks ATPase activity without affecting surface expression of the Na+ pump
-
-
?
additional information
?
-
the complexity of signalling by the ubiquitous second messenger cAMP is enhanced by multiple regulatory susceptibilities of its synthesis by adenylyl cyclases and degradation by phosphodiesterases, ACs receive regulatory signals from multiple sources, such as G-proteins, protein kinases, growth factors and Ca2+
-
-
?
additional information
?
-
-
the mu-opioid selective agonists, sufentanil and DAMGO, stimulate 5'-(gamma-thio)-triphosphate binding and inhibit forskolin-stimulated adenylyl cyclase activity, through a mechanism involving pertussis toxin, PTX, sensitive Gai/o subunits, the enhanced analgesic response following combined nimodipine treatment with sufentanil is associated with adenylyl cyclase supersensitivity to the opioid inhibitory effect through a mechanism involving PTX-resistant G protein subunits, overview
-
-
?
additional information
?
-
-
the pituitary adenylate cyclase-activating polypeptide type 1 receptor, PAC1-R, a member of the 7-transmembrane domain, group 2 G-protein coupled receptor family, modulate neurotransmission and neurotrophic actions, its activation is pronociceptive. Blockade of the PAC1-R/PACAP complex by PACAP 6-38, a PAC1-R antagonist, can effectively attenuate thermal hyperalgesia and mechanical allodynia associated with inflammatory and neuropathic pain states, overview
-
-
?
additional information
?
-
the transmembrane isozymes is regulated by forskolin and G proteins, while the soluble isozyme is insensitive
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP
3',5'-cyclic AMP + diphosphate
ATP
3',5'-cyclic-AMP + diphosphate
additional information
?
-
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
-
-
?
ATP
3',5'-cyclic AMP + diphosphate
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
-
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
adenylate cyclase-activating polypeptide type 1 receptor, PAC1-R, is involved in cAMP signalling in the pituitary gland
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
Ca2+-dependent adenylyl cyclases play a specific role in recovery from adaptive presynaptic silencing, involvement of the cAMP pathway in the basal balance between silenced and active synapses, as well as the recovery of baseline function after depolarization-induced presynaptic silencing, e.g. by glutamate, although isozymes AC1 and AC8 are not crucial for the baseline balance between silent and active synapses, overview. But AC8 plays a particularly important role in rapidly resetting the balance of active to silent synapses after adaptation to strong activity
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
capacitative Ca2+ entry via plasma membrane pore-forming component Orai1, i.e. Ca2+ release-activated Ca2+ modulator 1 or CRACM1, and stromal interacting molecule 1, STIM1, regulates adenylyl cyclase type 8, other modes of Ca2+ entry, including those activated by arachidonate and the ionophore ionomycin, are ineffective, detailed overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
interaction of mu-opioid receptors with G proteins and adenylyl cyclase in lumbar segments of the spinal cord, regulation, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
regulation of epithelial Na+ transport by soluble adenylyl cyclase in kidney collecting duct cells, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
soluble isozymes sAC play a unique function in male germ cells, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the adenylyl cyclase signaling cascade is involved in nicotine dependence and withdrawal, but also mediates numerous other neurotransmitter responses, effects of nicotine on adenylate cyclase enzyme activity: adolescent nicotine exposure elicits persistent suppression of basal adenylate cyclase activity and eventual compromise of responses to beta-adrenergic receptor stimulation, with effects emerging in late adulthood, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme is involved in beta1-AR signaling system that modulates intracellular Ca2+ in the heart. The enzyme is involved in mediation of the antiarrhymthmic effect of electro-acupuncture in the heart, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme is one of the signal transducing systems implicated in the regulation of the cardiovascular system and plays a role in signaling in vascular smooth muscle cells, which is decreased by oxidative stress, induced by high glucose, along with the expression of Gialpha proteins, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the enzyme modulates the cardiovascular response of posterior hypothalamic adenosine A2A receptor stimulation, adenylate cyclase, but not guanylate cyclase, mediates the depressor and bradycardiac actions of adenosine A2A receptors, overview
-
-
?
ATP
3',5'-cyclic-AMP + diphosphate
-
the soluble adenylyl cyclase is the main producer of glucose-induced cAMP in INS-1E insulinoma cells, while the transmembrane adenylyl cyclase does not play a role, overview
-
-
?
additional information
?
-
netrin-1 does not alter cAMP levels in axons attracted by this cue, and soluble adenylyl cyclase is not required for axon guidance to netrin-1
-
-
?
additional information
?
-
-
reduction of adenylyl cyclase activity induced by NaF and the increase in the Gi/Gs ratio can explain the changes in neurotransmission in olfactory bulbectomy rats, overview. Two weeks after surgery and compared to sham controls, olfactory bulbectomy rats display reduced NaF-stimulated adenylyl cyclase activity and increased Gi/Gs ratios in the hypothalamus, pre-frontal and cingulate cortices but not in the amygdala, hippocampus and caudate nucleus. No differences are found in basal or forskolin-stimulated conditions
-
-
?
additional information
?
-
soluble adenylyl cyclase inhibition blocks ATPase activity without affecting surface expression of the Na+ pump
-
-
?
additional information
?
-
the complexity of signalling by the ubiquitous second messenger cAMP is enhanced by multiple regulatory susceptibilities of its synthesis by adenylyl cyclases and degradation by phosphodiesterases, ACs receive regulatory signals from multiple sources, such as G-proteins, protein kinases, growth factors and Ca2+
-
-
?
additional information
?
-
-
the mu-opioid selective agonists, sufentanil and DAMGO, stimulate 5'-(gamma-thio)-triphosphate binding and inhibit forskolin-stimulated adenylyl cyclase activity, through a mechanism involving pertussis toxin, PTX, sensitive Gai/o subunits, the enhanced analgesic response following combined nimodipine treatment with sufentanil is associated with adenylyl cyclase supersensitivity to the opioid inhibitory effect through a mechanism involving PTX-resistant G protein subunits, overview
-
-
?
additional information
?
-
-
the pituitary adenylate cyclase-activating polypeptide type 1 receptor, PAC1-R, a member of the 7-transmembrane domain, group 2 G-protein coupled receptor family, modulate neurotransmission and neurotrophic actions, its activation is pronociceptive. Blockade of the PAC1-R/PACAP complex by PACAP 6-38, a PAC1-R antagonist, can effectively attenuate thermal hyperalgesia and mechanical allodynia associated with inflammatory and neuropathic pain states, overview
-
-
?
additional information
?
-
the transmembrane isozymes is regulated by forskolin and G proteins, while the soluble isozyme is insensitive
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2'(3')-O-(N-methylanthraniloyl)-ATP
-
catalytic heterodimer VC1-IIC2
2'(3')-O-(N-methylanthraniloyl)-GTP
-
catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP
-
catalytic heterodimer VC1-IIC2
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP
-
-
2',3'-O-(2,4,6-trinitrophenyl)-ADP
-
catalytic heterodimer VC1-IIC2
2',3'-O-(2,4,6-trinitrophenyl)-AMP
-
catalytic heterodimer VC1-IIC2
2',3'-O-(2,4,6-trinitrophenyl)-ATP
-
catalytic heterodimer VC1-IIC2
2',3'-O-(2,4,6-trinitrophenyl)-CTP
-
catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate
2',3'-O-(2,4,6-trinitrophenyl)-GDP
-
catalytic heterodimer VC1-IIC2
2',3'-O-(2,4,6-trinitrophenyl)-GTP
-
catalytic heterodimer VC1-IIC2
2',3'-O-(2,4,6-trinitrophenyl)-UTP
-
catalytic heterodimer VC1-IIC2
2-(1H-benzo[d]imidazole-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene) propanehydrazide
-
0.07 mM used in assay conditions
2-hydroxyestradiol
-
0.01 mM used in assay conditions
4-hydroxyestradiol
-
a catechol estrogen and sAC-selective inhibitor
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP
-
catalytic heterodimer VC1-IIC2
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP
-
catalytic heterodimer VC1-IIC2
catechol
-
and derivatives
DAMGO
-
a mu-opioid receptor agonist, inhibits the forskolin-activated enzyme, the combined treatment with sufentanil and nimodipine, an L-type Ca2+ channel blocker, increases mu-opioid-mediated inhibition of adenylyl cyclase and switched it to a predominantly PTX-resistant response, overview
epinephrine
-
overexposure to epinephrine inactivates adenylate cyclase
Foscarnet
-
a diphosphate analogue, is able to inhibit adenylate cyclase activity in cardiac myocytes, but does not inhibit activity of recombinant murine isozyme ACVI in virus-infected myocytes
Galphai2G203T
chronic treatment of HEK-293T cells reduces AC5 activity
-
inhibitory G protein
-
-
-
KH7
-
sAC-specific inhibitor
MANT-GTP
-
inhibits the VC1-IIC2 heterodimer
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP
-
catalytic heterodimer VC1-IIC2
noradrenaline
-
adenylate cyclase is almost completely inhibited by 0.5 mM noradrenaline
pertussis toxin
chronic treatment of HEK-293T cells reduces AC5 activity
-
PKC
-
inhibits AC6 activity
-
Ric8a
i.e., resistance to inhibitors of cholinesterase 8 homolog A, AC5 interacts with Ric8a through directly interacting at its N-terminus, selectively suppresses AC5 activity, does not further suppress AC5s activity in the presence of somatostatin, effectively suppresses the forskolin-stimulated activity of AC5, but not that of AC6. Treating cells with pertussis toxin or expressing a dominant negative Galphai mutant abolishes the suppressive effect, markedly suppresses the activation of AC5 induced by isoprenaline of a Galphas coupled receptor in an isoform-specific manner, while the isoprenaline-evoked activity of AC6 is not affected
-
siRNA
-
selectively reduces heterologous expression of AC6 without impact on the expression of AC2, reduces forskolin-activated AC6 activity, whereby diminishing forskolin-induced arborization
-
sufentanil
-
a mu-opioid receptor agonist, inhibits the forskolin-activated enzyme, the combined treatment with sufentanil and nimodipine, an L-type Ca2+ channel blocker, increases mu-opioid-mediated inhibition of adenylyl cyclase and switched it to a predominantly PTX-resistant response, overview
vitamin D
-
decreases parathyroid-induced stimulation of AC6 and induces a phosphorylation of AC6 in a PKC-dependent manner
Yotiao
-
the A-kinase anchoring protein Yotiao or AKAP9 binds and regulates adenylyl cyclase in brain, it inhibits AC2 and AC3, but has no effect on AC1 or AC9, the N-terminus of isozyme AC2, AC2-NT, acts as a competitive inhibitor of Yotiao-AC2 interactions, recombinantly expressed Yotiao from HEK293 cells
-
Ca2+
-
type II adenylyl cyclase
Ca2+
-
bradykinin receptor-mediated increases in the release of intracellular calcium inhibits AC6 activity
Ca2+
-
capacitative operated Ca2+ entry inhibits AC6
Ca2+
-
calcium entrance in the cell inhibits the enzyme
SQ22536
-
-
SQ22536
-
selective non-competitive inhibitor of adenylyl cyclase
additional information
-
full-length enzyme contains a large autoinhibitory C-terminal
-
additional information
-
Galpha0 is not sufficient to inhibit AC5 or AC6, inhibition requires an intact cell membrane or additional protein interactions that are absent in a reconstituted in vitro system
-
additional information
-
selective PKC inhibitor, abolishes cAMP accumulation by AC2
-
additional information
netrin-1 does not alter cAMP levels in axons attracted by this cue
-
additional information
-
oxidative stress decreases the enzyme stimulation through GTPgammaS, GSalpha proteins, and hormones, overview
-
additional information
soluble adenylyl cyclase inhibitors reduce not only basal Isc, but also Isc stimulated by two distinct agonists, forskolin and aldosterone, suggesting that soluble adenylyl cyclase activity may be regulating electrogenic Na+ transport at a site common to all pathways, soluble adenylyl cyclase inhibition blocks ATPase activity without affecting surface expression of the Na+ pump
-
additional information
-
structure-based development of adenylyl cyclase inhibitors, compounds exploiting the catechol estrogen binding site can produce potent, isoform discriminating adenylyl cyclase inhibitors, overview
-
additional information
the soluble isozyme contains a C-terminal autoinhibitory domain that reduces Vmax without affecting the substrate affinity
-
additional information
-
monovalent ions exhibit dose-dependent inhibition from 30 to 200 mM
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ethanol
AC2 is less responsive to ethanol than rat AC3 or human AC7, N-terminal 28-amino-acid region of the C1a domain and the C-terminal region of the AC molecule are important for the enhancement of AC activity by ethanol
5-CT
-
h5-HT6/rAC2 cell line highly responsive
5-HT
-
h5-HT6/rAC2 cell line highly responsive
A-77636
-
a dopamine receptor agonist, the activation by can be reversed by D1-receptor antagonists SCH23390, SKF83566, and butaclamol
acetazolamide
-
when apical membrane insertion of the vacuolar proton pumping ATPase is stimulated by treatment with acetazolamide, sAC is also concentrated in the apical membrane of A-intercalated cells
adrenaline
-
stimulates adenylate cyclase activity
alpha subunit of the guanine-nucleotide binding regulatory protein
-
activation
-
bovine serum albumin
-
stimulation
-
dihydrexidine
-
a dopamine receptor agonist, the activation by can be reversed by D1-receptor antagonists SCH23390, SKF83566, and butaclamol
ethanol
AC3 is far less responsive, AC2 is less responsive to ethanol than human AC7, N-terminal 28-amino-acid region of the C1a domain and the C-terminal region of the adenylate cyclase molecule are important for the enhancement of adenylate cyclase activity by ethanol
Gbetagamma
-
conditionally stimulates ACV and ACVI
-
glucagon-like peptide-1
-
stimulates the enzyme via activation of the specific G protein-coupled receptor GLP-1
-
GSalpha proteins
-
mediate stimulation of the adenylyl cyclase in case of hyperglycemia
-
guanosine 5'-(beta,gamma-imido)triphosphate
-
activation
HCO3-
-
50 mM, 5-20fold activation in the presence of Mg2+, 3fold activation in the presence of Mn2+
isoproterenol
-
stimulates AC6 resulting in a significant increase in the arborization process
lisuride
-
h5-HT6/rAC2 cell line highly responsive
Nicotine
-
nicotine treatment in adulthood produces an immediate increase in adenylate cyclase activity in males that disappears upon withdrawal, nicotine increases the activating effect of forskolin, especially in males, overview
phorbol 12-myristate 13-acetate
-
PKC-selective activator, stimulates AC2
pituitary adenylate cyclase activating polypeptide
-
-
-
pituitary adenylate cyclase-activating polypeptide
-
i.e. PACAP, a neurotrophic and neuromodulatory peptide, differentially modulates AMPA receptor-mediated current in CA1 pyramidal neurons by activation of PAC1 and VPAC2 receptors, both involving the cAMP/PKA pathway, mechanism and regulation, overview. It also enhances NMDA receptor-mediated currents
-
serotonin
-
AC2 stimulation followed by cAMP accumulation, no effect on AC5. AC2 co-transfected with Gs protein shows a synergistic effect on both baseline and agonist-stimulated cAMP accumulation. In the combined presence of Golf and AC2, the level of cAMP accumulation is enhanced in the agonist-stimulated cell line to levels equaling those of the AC2-expressing cell line only, with no effect on baseline activity. Similarly, when AC5 is co-expressed with Gs a synergistic effect with this pairing on both baseline and agonist-stimulated cAMP accumulation versus control can be observed. Because baseline activity is so high with the AC5/Gs pairing, the difference between stimulated and non-stimulated treatments is not significant. The AC5/Golf pairing fails to show any enhancement in cAMP accumulation upon serotonin stimulation, and no effect on baseline activity
stimulating G protein
-
-
-
sumatriptan
-
h5-HT6/rAC2 cell line highly responsive
Vasoactive intestinal peptide
-
activation
bicarbonate
-
-
bicarbonate
-
activates sAC in vivo and in vitro in a pH-dependent manner
Calmodulin
-
-
Calmodulin
-
stimulates AC8 in a Ca2+-dependent manner
Calmodulin
Ca2+ stimulates transmembrane isozyme AC8 via calmodulin
dopamine
-
140% activation at 0.1 mM, activation in hippocampus and striatum, the stimulation is partially inhibited, up to 48%, by oxotremorine, inhibition of stimulation is blocked by muscarinic toxin MT3, purified from Dendroaspis angusticeps snake venom, overview
dopamine
-
a dopamine receptor agonist, the activation by can be reversed by D1-receptor antagonists SCH23390, SKF83566, and butaclamol
Epidermal growth factor
-
increases cAMP accumulation in a GTP-dependent manner, enhances AC5 activity via phosphorylation of Galphas on one or more tyrosine residues
Epidermal growth factor
-
stimulates AC5, which is required for activation of a KCa1.1 channel in vascular smooth muscle and the subsequent upregulation of genes critical for cell proliferation
forskolin
-
-
forskolin
-
catalytic heterodimer VC1-IIC2
forskolin
-
forskolin-stimulated cAMP production is significantly increased to levels that do not differ between isoforms following the expression of AC1, AC2, AC5, or AC6
forskolin
-
activates the enzyme, the mu-opioid selective agonists sufentanil and DAMGO inhibit forskolin-stimulated adenylyl cyclase activity through a mechanism involving pertussis toxin sensitive Gai/o subunits, overview
forskolin
activates the transmembrane isozyme
forskolin
-
activation in a Mg2+-dependent manner
forskolin
-
activation in hippocampus, striatum, and amygdala. The stimulation is inhibited in vivo by oxotremorine, which is not affected by scopolamine. M4 is the main subtype responsible for muscarinic inhibition of forskolin-stimulated enzyme, overview
forskolin
-
direct adenylate cyclase agonist, causes smaller increases in contraction and Ca2+ transient amplitudes in aged compared to younger ventricular myocytes
forskolin
-
forskolin activation is elevated by nicotine treatment in adolescence, especially in males
forskolin
-
increases the number of active synapses
Galphas
-
-
-
Galphas
-
catalytic heterodimer VC1-IIC2
-
Galphas
-
stimulates the VC1-IIC2 heterodimer
-
GTPgammaS
-
stimulates the enzyme in hyperglycemic and control vascular smooth muscle cells
GTPgammaS
-
stimulation of activity occurs at 0.005 mM
NaF
-
-
additional information
completely insensitiv to forskolin and GTPgammaS
-
additional information
-
prolonged depolorization of cells, in the absence of Ca2+ leads to an increase in cAMP accumulation
-
additional information
-
chronic treatment with mu-opioid agonists leads to upregulation of the of the cAMP-signalling pathway
-
additional information
-
measurement of dopamine receptor agonist activation in a competitive assay with antagonists, e.g. SCH23390, overview
-
additional information
netrin-1 does not alter cAMP levels in axons attracted by this cue
-
additional information
-
no activation of the soluble isozyme by the transmembrane isozyme-specific activator forskolin
-
additional information
the soluble isozyme is insensitive to the regulation by forskolin and G proteins, but seems to be activated by a proteolytic mechanism
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000011 - 0.00011
2'(3')-O-(N-methylanthraniloyl)-ATP
0.000014 - 0.00013
2'(3')-O-(N-methylanthraniloyl)-GTP
0.0055
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.0067
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.0013 - 0.002
2',3'-O-(2,4,6-trinitrophenyl)-ADP
0.017 - 0.021
2',3'-O-(2,4,6-trinitrophenyl)-AMP
0.000081 - 0.0001
2',3'-O-(2,4,6-trinitrophenyl)-ATP
0.00011 - 0.00031
2',3'-O-(2,4,6-trinitrophenyl)-CTP
0.0081 - 0.0094
2',3'-O-(2,4,6-trinitrophenyl)-GDP
0.000083 - 0.00043
2',3'-O-(2,4,6-trinitrophenyl)-GTP
0.000092
2',3'-O-(2,4,6-trinitrophenyl)-UTP
0.0094 - 0.01
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP
0.058 - 0.1
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP
0.0094 - 0.011
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP
0.000011
2'(3')-O-(N-methylanthraniloyl)-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.00011
2'(3')-O-(N-methylanthraniloyl)-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.000014
2'(3')-O-(N-methylanthraniloyl)-GTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.00013
2'(3')-O-(N-methylanthraniloyl)-GTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.0013
2',3'-O-(2,4,6-trinitrophenyl)-ADP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.002
2',3'-O-(2,4,6-trinitrophenyl)-ADP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.017
2',3'-O-(2,4,6-trinitrophenyl)-AMP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.021
2',3'-O-(2,4,6-trinitrophenyl)-AMP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.000081
2',3'-O-(2,4,6-trinitrophenyl)-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.0001
2',3'-O-(2,4,6-trinitrophenyl)-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.00011
2',3'-O-(2,4,6-trinitrophenyl)-CTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.00031
2',3'-O-(2,4,6-trinitrophenyl)-CTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.0081
2',3'-O-(2,4,6-trinitrophenyl)-GDP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.0094
2',3'-O-(2,4,6-trinitrophenyl)-GDP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.000083
2',3'-O-(2,4,6-trinitrophenyl)-GTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.00043
2',3'-O-(2,4,6-trinitrophenyl)-GTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.000092
2',3'-O-(2,4,6-trinitrophenyl)-UTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.000092
2',3'-O-(2,4,6-trinitrophenyl)-UTP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.0094
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.01
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.058
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
0.1
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.0094
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas
0.011
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP
-
VC1-IIC2 in the presence of 0.1 mM forskolin
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Kornblihtt, A.R.; Flawia, M.M.; Torres, H.N.
Manganese ion dependent adenylate cyclase activity in rat testes: purification and properties
Biochemistry
20
1262-1267
1981
Rattus norvegicus
brenda
Rodan, S.B.; Egan, J.J.; Golub, E.E.; Rodan, G.A.
Comparison of bone and osteosarcoma adenylate cyclase. Partial purification of membranes and kinetic properties of enzyme
Biochem. J.
185
617-627
1980
Rattus norvegicus
brenda
Stengel, D.; Hanoune, J.
Solubilization and physical characterization of the adenylate cyclase from rat-liver plasma membranes
Eur. J. Biochem.
102
21-34
1979
Rattus norvegicus
brenda
Neer, E.J.
Physical and functional properties of adenylate cyclase from mature rat testis
J. Biol. Chem.
253
5808-5812
1978
Rattus norvegicus
brenda
Braun, T.
Purification of soluble form of adenylyl cyclase from testes
Methods Enzymol.
195
130-136
1991
Rattus norvegicus
brenda
Neer, E.J.
The size of adenylate cyclase
J. Biol. Chem.
249
6527-6531
1974
Rattus norvegicus
brenda
Feinstein, P.G.; Schrader, K.A.; Bakalyar, H.A.; Tang, W-J.; Krupinski, J.; Gilman, A.G.; Reed, R.R.
Molecular cloning and characterization of a Ca2+/calmodulin-insensitive adenylyl cyclase from rat brain
Proc. Natl. Acad. Sci. USA
88
10173-10177
1991
Rattus norvegicus
brenda
Premont, R.T.; Matsuoka, I.; Mattei, M.G.; Pouille, Y.; Defer, N.; Hanoune, J.
Identification and characterization of a widely expressed form of adenylyl cyclase
J. Biol. Chem.
271
13900-13907
1996
Rattus norvegicus, Mus musculus (P51830), Mus musculus
brenda
Sethi, R.; Dhalla, K.S.; Shah, K.R.; Dhalla, N.S.
Characterization of adenylyl cyclase in heart sarcolemma in the absence or presence of alamethicin
Mol. Cell. Biol.
119
185-193
1993
Rattus norvegicus
brenda
Plesneva, S.A.; Nalivaeva, N.N.; Zhuravin, I.A.
Adenylate cyclase system of the rat striatum: regulatory properties and the effects of gangliosides
Neurosci. Behav. Physiol.
28
392-396
1998
Rattus norvegicus
brenda
Enomoto, L.; Takano, M.; Ariyoshi, S.; Asakawa, T.
Mechanism and properties of inhibition of purified rat brain adenylate cyclase by G protein beta gamma-subunits
Jpn. J. Pharmacol.
69
239-250
1995
Rattus norvegicus
brenda
Pozo, D.; Segura, J.J.; Carrero, I.; Guijarro, L.G.; Prieto, J.C.; Calvo, J.R.
Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes
Biochim. Biophys. Acta
1312
249-254
1996
Mus musculus, Rattus norvegicus
brenda
Nair, B.G.; Patel, T.B.
Inhibition of hepatic adenylate cyclase by NADH
Life Sci.
49
915-923
1991
Rattus norvegicus
brenda
Defer, N.; Best-Belpomme, M.; Hanoune, J.
Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase
Am. J. Physiol.
279
F400-F416
2000
Gallus gallus, Mus musculus, Rattus norvegicus
brenda
Jaiswal, B.S.; Conti, M.
Identification and functional analysis of splice variants of the germ cell soluble adenylyl cyclase
J. Biol. Chem.
276
31698-31708
2001
Mus musculus, Rattus norvegicus
brenda
Hatley, M.E.; Gilman, A.G.; Sunahara, R.K.
Expression, purification, and assay of cytosolic (catalytic) domains of membrane-bound mammalian adenylyl cyclases
Methods Enzymol.
345
127-140
2001
Canis lupus familiaris, Rattus norvegicus
brenda
Buck, J.; Sinclair, M.L.; Schapal, L.; Cann, M.J.; Levin, L.R.
Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals
Proc. Natl. Acad. Sci. USA
96
79-84
1999
Rattus norvegicus (Q9Z286)
brenda
Tesmer, J.J.G.; Sunahara, R.K.; Johnson, R.A.; Gosselin, G.; Gilman, A.G.; Sprang, S.R.
Two-metal-ion catalysis in adenylyl cyclase
Science
285
756-760
1999
Rattus norvegicus
brenda
Yoshimura, M.; Pearson, S.; Kadota, Y.; Gonzalez, C.E.
Identification of ethanol responsive domains of adenylyl cyclase
Alcohol. Clin. Exp. Res.
30
1824-1832
2006
Rattus norvegicus (P21932), Rattus norvegicus (P26769), Homo sapiens (P51828)
brenda
Paunescu, T.G.; Da Silva, N.; Russo, L.M.; McKee, M.; Lu, H.A.; Breton, S.; Brown, D.
Association of soluble adenylyl cyclase with the V-ATPase in renal epithelial cells
Am. J. Physiol. Renal Physiol.
294
F130-F138
2008
Mus musculus, Rattus norvegicus
brenda
Wang, S.C.; Lai, H.L.; Chiu, Y.T.; Ou, R.; Huang, C.L.; Chern, Y.
Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor
Biochem. J.
406
383-388
2007
Rattus norvegicus (Q04400)
brenda
Linder, J.U.
Class III adenylyl cyclases: molecular mechanisms of catalysis and regulation
Cell. Mol. Life Sci.
63
1736-1751
2006
Bacillus anthracis, Bordetella pertussis, Saccharomyces cerevisiae, Caenorhabditis elegans, Chlamydomonas reinhardtii, Chloroflexus aurantiacus, Dictyostelium discoideum, Drosophila melanogaster, Escherichia coli, Euglena gracilis, Mus musculus, Myxococcus xanthus, Pseudomonas aeruginosa, Rattus norvegicus, Sinorhizobium meliloti, Schizosaccharomyces pombe, Arthrospira platensis, Trypanosoma brucei, Ustilago maydis, Yersinia enterocolitica, Mycobacterium tuberculosis (P9WQ35), Nostoc sp. PCC 7120 = FACHB-418 (Q7A2D9), Nostoc sp. PCC 7120 = FACHB-418 (Q8YMH0), Nostoc sp. PCC 7120 = FACHB-418 (Q8YVS0), Mycobacterium tuberculosis H37Rv (P9WQ35)
brenda
Gros, R.; Ding, Q.; Chorazyczewski, J.; Pickering, J.G.; Limbird, L.E.; Feldman, R.D.
Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization
Circ. Res.
99
845-852
2006
Rattus norvegicus
brenda
Beazely, M.A.; Watts, V.J.
Regulatory properties of adenylate cyclases type 5 and 6: A progress report
Eur. J. Pharmacol.
535
1-12
2006
Cricetulus griseus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Gao, X.; Sadana, R.; Dessauer, C.W.; Patel, T.B.
Conditional stimulation of type V and VI adenylyl cyclases by G protein betagamma subunits
J. Biol. Chem.
282
294-302
2007
Canis lupus familiaris, Homo sapiens, Rattus norvegicus
brenda
Nawoschik, S.P.; Olsen, M.; Smith, D.L.; Khawaja, X.
Stable expression of adenylyl cyclase 2 leads to the functional rescue of human 5-HT6 receptor in a CHODUKX cell line
J. Pharmacol. Toxicol. Methods
55
323-331
2007
Rattus norvegicus
brenda
Watts, V.J.
Adenylyl cyclase isoforms as novel therapeutic targets: an exciting example of excitotoxicity neuroprotection
Mol. Interv.
7
70-73
2007
Mus musculus, Rattus norvegicus
brenda
Mou, T.C.; Gille, A.; Suryanarayana, S.; Richter, M.; Seifert, R.; Sprang, S.R.
Broad specificity of mammalian adenylyl cyclase for interaction with 2,3-substituted purine- and pyrimidine nucleotide inhibitors
Mol. Pharmacol.
70
878-886
2006
Canis lupus familiaris, Rattus norvegicus
brenda
Antoni, F.A.; Wiegand, U.K.; Black, J.; Simpson, J.
Cellular localisation of adenylyl cyclase: a post-genome perspective
Neurochem. Res.
31
287-295
2006
Homo sapiens, Macaca sp., Mus musculus, Rattus norvegicus, Mus musculus C57BL/6
brenda
Willoughby, D.; Cooper, D.M.
Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains
Physiol. Rev.
87
965-1010
2007
Aplysia sp., Canis lupus familiaris, Oryctolagus cuniculus, Dictyostelium discoideum, Drosophila sp. (in: flies), Homo sapiens, Mus musculus, Paramecium sp., Rattus norvegicus, Tetrahymena sp., Plasmodium sp.
brenda
Sinha, S.C.; Sprang, S.R.
Structure, mechanism, regulation and evolution of class III nucleotidyl cyclases
Rev. Physiol. Biochem. Pharmacol.
157
105-140
2007
Aeromonas hydrophila, Bacillus anthracis, Prevotella ruminicola, Bordetella pertussis, Canis lupus familiaris, Caulobacter vibrioides, Escherichia sp., Haemophilus sp., Mycobacterium tuberculosis, Yersinia pestis, Pseudomonas sp., Pseudomonas aeruginosa, Rattus norvegicus, Rhizobium etli, Sinorhizobium meliloti, Arthrospira platensis, Trypanosoma brucei, Vibrio parahaemolyticus, Yersinia sp.
brenda
Li, Y.; Descorbeth, M.; Anand-Srivastava, M.B.
Role of oxidative stress in high glucose-induced decreased expression of Gialpha proteins and adenylyl cyclase signaling in vascular smooth muscle cells
Am. J. Physiol. Heart Circ. Physiol.
294
H2845-H2854
2008
Rattus norvegicus
brenda
Lee, C.B.; Koh, H.C.
Modification of the cardiovascular response of posterior hypothalamic adenosine A(2A) receptor stimulation by adenylate cyclase and KATP channel blockade in anesthetized rats
Auton. Neurosci.
146
70-75
2009
Rattus norvegicus
brenda
Slotkin, T.A.; Ryde, I.T.; Mackillop, E.A.; Bodwell, B.E.; Seidler, F.J.
Adolescent nicotine administration changes the responses to nicotine given subsequently in adulthood: adenylyl cyclase cell signaling in brain regions during nicotine administration and withdrawal, and lasting effects
Brain Res. Bull.
76
522-530
2008
Rattus norvegicus
brenda
Wann, B.P.; DAnjou, B.; Bah, T.M.; Webster, H.H.; Godbout, R.; Rousseau, G.
Effect of olfactory bulbectomy on adenylyl cyclase activity in the limbic system
Brain Res. Bull.
79
32-36
2009
Homo sapiens, Rattus norvegicus
brenda
Costa, L.; Santangelo, F.; Li Volsi, G.; Ciranna, L.
Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus
Hippocampus
19
99-109
2009
Rattus norvegicus
brenda
Gao, M.H.; Tang, T.; Guo, T.; Miyanohara, A.; Yajima, T.; Pestonjamasp, K.; Feramisco, J.R.; Hammond, H.K.
Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes
J. Biol. Chem.
283
33527-33535
2008
Mus musculus, Rattus norvegicus
brenda
Hallows, K.R.; Wang, H.; Edinger, R.S.; Butterworth, M.B.; Oyster, N.M.; Li, H.; Buck, J.; Levin, L.R.; Johnson, J.P.; Pastor-Soler, N.M.
Regulation of epithelial Na+ transport by soluble adenylyl cyclase in kidney collecting duct cells
J. Biol. Chem.
284
5774-5783
2009
Rattus norvegicus (Q9Z286)
brenda
Ramos, L.S.; Zippin, J.H.; Kamenetsky, M.; Buck, J.; Levin, L.R.
Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells
J. Gen. Physiol.
132
329-338
2008
Rattus norvegicus
brenda
Schlicker, C.; Rauch, A.; Hess, K.C.; Kachholz, B.; Levin, L.R.; Buck, J.; Steegborn, C.
Structure-based development of novel adenylyl cyclase inhibitors
J. Med. Chem.
51
4456-4464
2008
Rattus norvegicus, Arthrospira platensis (O32393), Homo sapiens (Q96PN6), Homo sapiens
brenda
Moore, S.W.; Lai Wing Sun, K.; Xie, F.; Barker, P.A.; Conti, M.; Kennedy, T.E.
Soluble adenylyl cyclase is not required for axon guidance to netrin-1
J. Neurosci.
28
3920-3924
2008
Mus musculus (Q8C0T9), Rattus norvegicus (Q9Z286)
brenda
Moulder, K.L.; Jiang, X.; Chang, C.; Taylor, A.A.; Benz, A.M.; Conti, A.C.; Muglia, L.J.; Mennerick, S.
A specific role for Ca2+-dependent adenylyl cyclases in recovery from adaptive presynaptic silencing
J. Neurosci.
28
5159-5168
2008
Mus musculus, Rattus norvegicus
brenda
Davis-Taber, R.; Baker, S.; Lehto, S.G.; Zhong, C.; Surowy, C.S.; Faltynek, C.R.; Scott, V.E.; Honore, P.
Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states
J. Pain
9
449-456
2008
Rattus norvegicus
brenda
Vonk, A.; Reinart, R.; Rinken, A.
Modulation of adenylyl cyclase activity in rat striatal homogenate by dopaminergic receptors
J. Pharmacol. Sci.
108
63-70
2008
Rattus norvegicus
brenda
Gao, J.; Zhang, L.; Wang, Y.; Lu, B.; Cui, H.; Fu, W.; Wang, H.; Yu, Y.; Yu, X.
Antiarrhythmic effect of acupuncture pretreatment in rats subjected to simulative global ischemia and reperfusion - involvement of adenylate cyclase, protein kinase a, and L-type ca(2+) channel
J. Physiol. Sci.
58
389-396
2008
Rattus norvegicus
brenda
Lomovatskaya, L.A.; Romanenko, A.S.; Filinova, N.V.
Plant adenylate cyclases
J. Recept. Signal Transduct. Res.
28
531-542
2008
Euglena gracilis, Medicago sativa, Nicotiana tabacum, Solanum tuberosum, Bryum argenteum, Rattus norvegicus (Q9Z286)
brenda
Farrell, S.R.; Howlett, S.E.
The age-related decrease in catecholamine sensitivity is mediated by ss(1)-adrenergic receptors linked to a decrease in adenylate cyclase activity in ventricular myocytes from male Fischer 344 rats
Mech. Ageing Dev.
129
735-744
2008
Rattus norvegicus
brenda
Martin, A.C.; Willoughby, D.; Ciruela, A.; Ayling, L.J.; Pagano, M.; Wachten, S.; Tengholm, A.; Cooper, D.M.
Capacitative Ca2+ entry via Orai1 and STIM1 regulates adenylyl cyclase type 8
Mol. Pharmacol.
75
830-842
2009
Mus musculus, Rattus norvegicus (P40146)
brenda
Sanchez, G.; Colettis, N.; Vazquez, P.; Cervenansky, C.; Aguirre, A.; Quillfeldt, J.A.; Jerusalinsky, D.; Kornisiuk, E.
Muscarinic inhibition of hippocampal and striatal adenylyl cyclase is mainly due to the M(4) receptor
Neurochem. Res.
34
1363-1371
2009
Rattus norvegicus
brenda
Mostany, R.; Diaz, A.; Valdizan, E.M.; Rodriguez-Munoz, M.; Garzon, J.; Hurle, M.A.
Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits
Neuropharmacology
54
989-997
2008
Rattus norvegicus
brenda
Farrell, J.; Ramos, L.; Tresguerres, M.; Kamenetsky, M.; Levin, L.R.; Buck, J.
Somatic soluble adenylyl cyclase isoforms are unaffected in Sacy tm1Lex/Sacy tm1Lex knockout mice
PLoS ONE
3
e3251
2008
Rattus norvegicus
brenda
Piggott, L.A.; Bauman, A.L.; Scott, J.D.; Dessauer, C.W.
The A-kinase anchoring protein Yotiao binds and regulates adenylyl cyclase in brain
Proc. Natl. Acad. Sci. USA
105
13835-13840
2008
Rattus norvegicus
brenda
Bennun, A.
Characterization of the norepinephrine-activation of adenylate cyclase suggests a role in memory affirmation pathways Overexposure to epinephrine inactivates adenylate cyclase, a causal pathway for stress-pathologies
BioSystems
100
87-93
2010
Rattus norvegicus
brenda
Liou, J.T.; Liu, F.C.; Mao, C.C.; Hsin, S.T.; Lui, P.W.
Adenylate cyclase inhibition attenuates neuropathic pain but lacks pre-emptive effects in rats
Can. J. Anesth.
56
763-769
2009
Rattus norvegicus
brenda
Latini, S.; Chiarpotto, M.; Muciaccia, B.; Vaccari, S.; Barberi, M.; Guglielmo, M.C.; Stefanini, M.; Cecconi, S.; Canipari, R.
Inhibitory effect of pituitary adenylate cyclase activating polypeptide on the initial stages of rat follicle development
Mol. Cell. Endocrinol.
320
34-44
2010
Rattus norvegicus
brenda
Mato, S.; Vidal, R.; Castro, E.; Diaz, A.; Pazos, A.; Valdizan, E.M.
Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms
Mol. Pharmacol.
77
424-434
2010
Rattus norvegicus
brenda
Tupal, S.; Faingold, C.
Inhibition of adenylyl cyclase in amygdala blocks the effect of audiogenic seizure kindling in genetically epilepsy-prone rats
Neuropharmacology
59
107-111
2010
Rattus norvegicus
brenda
Gao, M.H.; Tang, T.; Lai, N.C.; Miyanohara, A.; Guo, T.; Tang, R.; Firth, A.L.; Yuan, J.X.; Hammond, H.K.
Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant
Mol. Pharmacol.
79
381-388
2011
Rattus norvegicus
brenda
Imber, A.N.; Santin, J.M.; Graham, C.D.; Putnam, R.W.
A HCO3--dependent mechanism involving soluble adenylyl cyclase for the activation of Ca2+ currents in locus coeruleus neurons
Biochim. Biophys. Acta
1842
2569-2578
2014
Rattus norvegicus
brenda
Nikolic, I.; Mitrovic, M.; Zelen, I.; Zaric, M.; Kastratovic, T.; Stanojevic, M.; Nenadovic, M.; Stojanovic, T.
Inhibitory role of monovalent ions on rat brain cortex adenylyl cyclase activity
J. Enzyme Inhib. Med. Chem.
28
1061-1066
2013
Rattus norvegicus
brenda